Cougar Biotechnology Presents Positive CB7630 Phase I And Phase II Data At ASCO 2008 Genitourinary Cancers Symposium

Cougar Biotechnology, Inc. (NASDAQ:CGRB) announced that results from ongoing Phase I and Phase II clinical trials of Cougar’s investigational drug, CB7630 (abiraterone acetate), were presented at the ASCO Genitourinary Cancers Symposium that is currently taking place in San Francisco, California. The data was presented today in both an oral presentation and two poster presentations.

More: continued here

Filed under: Prostate on February 19th, 2008